BAC
Bank of America Corporation
BAC has slightly lower modeled downside risk, despite its lower overall score.
CNOB
ConnectOne Bancorp, Inc.
CNOB has a slight edge over BAC overall, supported by stronger fundamentals.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CNOB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CNOB's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNOB.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CNOB in the historical PE scenario, which offers more potential upside but is not a forecast.
CNOB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.8x | $22.45 | -32% |
| Forward | 9.3x | $32.78 | — |
| Fair | 10x | $29.90 | -8.8% |
| Current | 11x | $32.78 | — |
| Expensive | 15x | $41.53 | +27% |
Historical ranges are pointers, not guarantees.
CNOB's PE is 11x, but its earnings don't support one, so it isn't a reliable read right now.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
CNOB Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CNOB, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CNOB on earnings, with more consistent year-over-year improvement.
CNOB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.51 | +23% |
| Q3 2026 | $2.86 | +131% |
| Q2 2026 | $3.05 | +251% |
| Q1 2026 | $1.73 | -6.5% |
| Q4 2025 | $1.50 | -15% |
| Q3 2025 | $1.24 | -29% |
| Q2 2025 | $0.87 | -53% |
| Q1 2025 | $1.85 | -2.1% |
| Q4 2024 | $1.77 | -14% |
CNOB earned $2.86 per share over the past year, up 131% from the year before. Its recent earnings include one-off gains.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
CNOB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.8M | -15% |
| Q2 2026 | $121.6M | +45% |
| Q1 2026 | $115.6M | +65% |
| Q4 2025 | $112.6M | +65% |
| Q3 2025 | $121.4M | +85% |
| Q2 2025 | $84.1M | +28% |
| Q1 2025 | $70.2M | +9.4% |
| Q4 2024 | $68.5M | +3.7% |
CNOB's revenue is growing: $103M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 41% | -5.9 points |
| Q2 2026 | 48% | +78 points |
| Q1 2026 | 45% | +6.4 points |
| Q4 2025 | 47% | +8.7 points |
| Q3 2025 | 47% | +12 points |
| Q2 2025 | -30% | -69 points |
| Q1 2025 | 39% | +3.1 points |
| Q4 2024 | 39% | 0 points |
CNOB has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
CNOB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $84.9M | +150% |
| Q2 2026 | $33.7M | +427% |
| Q1 2026 | $14M | -4.1% |
| Q4 2025 | $46.1M | +54% |
| Q3 2025 | $33.9M | +$49.5M |
| Q2 2025 | $6.4M | -71% |
| Q1 2025 | $14.6M | -28% |
| Q4 2024 | $30M | +21% |
CNOB has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CNOB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CNOB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +52K shares |
| 1 year | 0% | -6K shares |
| 3 years | +30% | +11.6M shares |
| 5 years | +27% | +10.6M shares |
| Available history | +27% | +10.8M shares |
CNOB has 50M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.6M |
| Q2 2026 | — |
| Q1 2026 | $2.4M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
CNOB spent $4M buying back its own shares over the past year, after none the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CNOB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 4.4x | High |
| Q4 2025 | 5.7x | High |
| Q3 2025 | 5.1x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 4.0x | Elevated |
CNOB has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CNOB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 65.4 | Neutral |
CNOB's weekly RSI is 59 (neutral) and its Stochastic is 65 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
CNOB PE vs Financial Services Sector
| Metric | CNOB | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 12% below |
| PE % | 62 | 63 | 1 pt below |
CNOB has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CNOB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 4% above |
| 20 week MA | $32.1 | 2.2% above |
| 50 week MA | $29.8 | 10% above |
| 100 week MA | $26.9 | 22% above |
| 200 week MA | $23.7 | 38% above |
CNOB has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CNOB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.6 | $19.6 | -24% |
| 2021 | $19.6 | $32.1 | +64% |
| 2022 | $32.1 | $24.3 | -24% |
| 2023 | $24.3 | $22.9 | -5.9% |
| 2024 | $22.9 | $22.7 | -1.1% |
| 2025 | $22.7 | $26.9 | +19% |
| 2026 YTD | $26.9 | $32.8 | +22% |
CNOB has the edge over BAC on returns for 2026, with the stronger performance.